Published in final edited form as:

Chem Res Toxicol. 2014 January 21; 27(1): 111–118. doi:10.1021/tx400356y.

Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-*N*-oxide

Xiulong Shen[§], Anuruddha Rajapakse[§], Fabio Gallazzi[†], Venkatraman Junnotula[§], Tarra Fuchs-Knotts[§], Rainer Glaser[§], and Kent S. Gates^{§,†,*}

[§]University of Missouri, Department of Chemistry, 125 Chemistry Building, Columbia, MO 65211

[†]University of Missouri, Department of Biochemistry, 125 Chemistry Building, Columbia, MO 65211

[†]University of Missouri, Structural Biology Core, Columbia, MO 65211, USA

Abstract

The 1,2,4-benzotriazine 1,4-dioxides are an important class of potential anticancer drugs that selectively kill the low-oxygen (hypoxic) cells found in solid tumors. These compounds undergo intracellular one-electron enzymatic reduction to yield an oxygen-sensitive drug radical intermediate that partitions forward, under hypoxic conditions, to generate a highly reactive secondary radical that causes cell killing DNA damage. Here we characterized bioeductively-activated, hypoxia-selective DNA-strand cleavage by 1,2,4-benzotriazine 1,4-dioxide. We found that one-electron enzymatic activation of 1,2,4-benzotriazine 1,4-dioxide under hypoxic conditions in the presence of the deuterium atom donor methanol-*d*₄ produced non-deuterated mono-*N*-oxide metabolites. This and the results of other isotopic labeling studies provided evidence against the generation of atom-abstrating drug radical intermediates and are consistent with a DNA-damage mechanism involving release of hydroxyl radical from enzymatically-activated 1,2,4-benzotriazine 1,4-dioxides.

Introduction

In cancer chemotherapy, there is a continuing need for the development of drugs that selectively target malignant tissue.¹ Toward this end, the poorly developed vascular system in tumors creates a low oxygen environment that may be exploited by some small molecules for the selective killing of cancer cells.² The 1,2,4-benzotriazine 1,4-di-*N*-oxides are an important class of hypoxia-selective cytotoxins.^{2–7} Tirapazamine (**1a**) is the lead compound in this class of drugs, but many analogs in this structural family display similar bioactivities,^{3–6} and the relatively new agent SN30000/CEN-209 (**4**) is advancing toward clinical development.^{8,9}

*To whom correspondence should be addressed: gatesk@missouri.edu; phone: (573) 882-6763; FAX: (573) 882-2754.

Supporting Information: Results of control experiments related to DNA strand cleavage, LC-MS/MS data, and NMR data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The medicinal action of tirapazamine and other 1,2,4-benzotriazine 1,4-dioxides involves intracellular one-electron enzymatic reduction to yield an oxygen-sensitive drug radical intermediate (**2**).¹⁰⁻¹³ In normally-oxygenated tissue, **2** is simply oxidized by O₂ back to the parent compound **1**.^{13,14} However, under hypoxic conditions, the radical intermediate **2** partitions forward to generate a highly reactive secondary radical that kills cells via abstraction of hydrogen atoms from the 2'-deoxyribose phosphate backbone of DNA.¹⁵⁻²² The mono-*N*-oxide **3** is the major drug metabolite generated in this process.^{15,16,23} The exact nature of the ultimate DNA-damaging radical generated following bioreductive activation of the 1,2,4-benzotriazine 1,4-dioxides remains a topic of ongoing study, with two different possibilities considered in the recent literature. First, evidence has been presented that is consistent with the release of hydroxyl radical (HO•) from the protonated drug radical **2** (Scheme 1).^{21,24-28} This mechanism adequately accounts for the DNA-damaging properties and the hypoxia-selective cytotoxicity of many different heterocyclic *N*-oxides including 1,2,4-benzotriazine 1,4-dioxides,^{21,24-26,29} quinoxaline 1,4-dioxides,³⁰⁻³³ 1,2-dihydro-4-phenylimidazo[1,2-*a*]pyrido[3,2-*e*]pyrazine 5-oxides,³⁴ and phenazine 5,10-dioxides.³⁵ A second mechanistic proposal suggests that the tirapazamine radical **2** can undergo dehydration to generate a highly reactive benzotriazinyl radical **5** that abstracts hydrogen atoms from DNA.³⁶⁻⁴⁰ To account for the bioactivities of other 1,2,4-benzotriazine 1,4-dioxide analogues such as **1b**, the dehydration mechanism was expanded to include a family of hypothetical processes that generate aryl radical intermediates such as **6**.³⁸

Isotopic labeling experiments have the potential to distinguish which of these two mechanistic pathways is operative. For example, the proposed generation of the aryl radical **6** from **2b** in the presence of a deuterium atom donor will yield the corresponding deuterated drug metabolite **3c**,^{41,42} whereas release of hydroxyl radical from **2b** will produce the non-deuterated metabolite **3b**. Here we report the results of such isotopic labeling studies carried out in the context of compound **1b**. We reasoned that **1b** was good subject for mechanistic studies because this agent displays hypoxia-selective cytotoxicity comparable to tirapazamine (**1a**)³ and has been proposed to generate the DNA-damaging aryl radical **6**.³⁸ However, the ability of **1b** to carry out in vitro reductively-activated, hypoxia-selective DNA strand cleavage in a manner similar to tirapazamine had not been previously demonstrated. Therefore, before undertaking isotopic labeling studies, we characterized the DNA-damaging properties of **1b**.^{13,21,25,43} We found that **1b** displays bioreductively-activated, hypoxia-selective DNA-cleaving properties analogous to the lead compound tirapazamine (**1a**). The results of several different isotopic labeling studies provided evidence against the generation of atom-abstracting drug radicals such as **6** following one-electron enzymatic activation of **1b** under hypoxic conditions.

Materials and Methods

Materials

Materials were of the highest purity available and were obtained from the following sources: Cytochrome P450 reductase, NADPH, sodium phosphate, mannitol, DMSO, desferal, catalase, superoxide dismutase (SOD), *tert*-butyl nitrite, silica gel (0.04-0.063 mm pore size)

for column chromatography, and silica gel plates for thin layer chromatography from Sigma Chemical Co. (St. Louis, MO); agarose from Seakem; HPLC grade solvents (acetonitrile, methanol, ethanol, tert-butyl alcohol, ethyl acetate, hexane, and acetic acid) from Fischer (Pittsburgh, PA); ethidium bromide from Roche Molecular Biochemicals (Indianapolis, IN); deuterated NMR solvents (deuterium oxide, D 99.96%, methanol- d_4 , D 99.8%, N,N -dimethylformamide- d_7 , D 99.5%; acetone- d_6 , D 99.8%) were from Cambridge Isotope Laboratories (Andover, MA). Compounds **1a** and **1b** were prepared by routes described previously in the literature.^{3,23,44} Compound **3b** was prepared via the same general procedure used for **1b**.³ and the spectral data of this product matched that published previously.³⁸

DNA Cleavage Assays

DNA strand cleavage reactions were carried out as described previously.^{32,35} Briefly, in a hypoxic DNA-cleavage assay, agents such as **1a**, **1b**, or **1d** (25–150 μ M) were incubated with supercoiled plasmid DNA (33 μ g/mL, pGL-2 Basic), NADPH (500 μ M), cytochrome P450 reductase (33 mU/mL, where one unit is defined as the amount of enzyme required to cause the reduction of 1.0 μ mole of cytochrome c by NADPH per minute at pH 7.4 at 37 $^{\circ}$ C), catalase (100 μ g/mL), superoxide dismutase (10 μ g/mL), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (0.5–3.3% v/v), and desferal (deferioxamine mesylate salt, 10 mM) under anaerobic conditions at 25 $^{\circ}$ C for 4 h. All components of the reactions except enzymes, NADPH, and DNA were degassed by three freeze-pump-thaw cycles. Enzymes, NADPH, and DNA were diluted with degassed water in an argon-filled glove bag to prepare stock solutions. Reactions were initiated by the addition of cytochrome P450 reductase, wrapped in aluminum foil to prevent exposure to light, and incubated in an argon-filled glove bag. Following incubation, the reactions were quenched by addition of 4 μ L of loading buffer containing bromophenol blue dye and were loaded onto a 0.9% agarose gel. The gel was electrophoresed for approximately 2 h at 83 V in 1 $\times$ TAE buffer. The gel was then stained in a solution of aqueous ethidium bromide (0.5 μ g/mL) for 15 min, destained in fresh distilled water for 15 min, and the DNA in the gel visualized by UV-transillumination. The amount of DNA in each band was quantified using an Alpha Innotech IS-1000 digital imaging system. Buffers for the reactions performed in D_2O were prepared using the same mixture of phosphate buffer salts used in the H_2O experiments, as described by others.^{45,46}

Synthesis of 4-deutero-1,2,4-benzotriazine 1,4-dioxide (**1c**)

In a 25 mL round bottom flask, *tert*-butyl nitrite (0.25 mL, 2.10 mmol) was added to DMF- d_7 (2 mL) and heated to 65 $^{\circ}$ C. To this mixture, a solution of **1a** (100 mg) in DMF- d_7 (2 mL) and was added dropwise over the course of 15 min. The reaction was monitored by thin layer chromatography every 10 min until all starting material was consumed. The reaction mixture was then cooled to room temperature and the DMF- d_7 was removed by high vacuum. Column chromatography on silica gel eluted with 1:1 ethyl acetate-hexane gave **1c** as a yellow solid (23 mg, 25%). R_f 0.60 (100% ethyl acetate): 1H NMR (DMSO, 500 MHz): δ 8.39 (d, J = 8.5 Hz, 1H), 8.36 (d, J = 8.5 Hz, 1H), 8.14 (ddd, J = 8.5, 7.5, 1.0 Hz, 1H), 8.10 (ddd, J = 8.5, 7.5, 1.0 Hz, 1H). ^{13}C -NMR (DMSO, 125.8 MHz): δ 142.2 (t, J = 33.3 Hz), 141.0, 136.0, 135.6, 133.3, 121.5, 119.4. HRMS (ES^+ , $[M+H]$) m/z calcd $C_7H_5DN_3O_2$ calcd mass 165.0523; actual mass 165.0515.

Synthesis of 1,2,4-benzotriazine (7)

The benzotriazine **7** was prepared via a modification of the procedures described by Fuchs *et al.* and Mason and Tennant.^{23,47} To a solution of **3b** (300 mg, 2.04 mmol) in 70% ethanol-water (40 mL) was added sodium dithionite (710 mg, 4.08 mmol). The resulting suspension was refluxed for 2 h, an additional aliquot of sodium dithionite (305 mg, 2.04 mmol) added, and the suspension refluxed for another 30 min, at which time all starting material was consumed (as judged by TLC). The solvent was removed by rotary evaporation and the resulting pale yellow residue purified by column chromatography on silica gel eluted with 30% ethyl acetate-hexane to yield **7** as pale yellow solid (154 mg, 58%). $R_f = 0.57$ (30% ethyl acetate/hexane): $^1\text{H-NMR}$ (DMSO, 500 MHz): δ 10.13 (s, 1H), 8.61 (d, $J = 8.5$ Hz, 1H), 8.18-8.24 (m, 2H), 8.10 (ddd, $J = 8.5, 6.5, 1.5$ Hz, 1H). $^{13}\text{C-NMR}$ (DMSO, 125.8 MHz): δ 154.1, 148.1, 140.1, 136.8, 132.2, 129.5, 129.0. Spectral data matched that reported by Boyd *et al.*⁴⁸

LC-MS/MS Analysis of Mixtures Generated by In Vitro Hypoxic Metabolism of **1b** and **1c**

In the LC-MS isotope incorporation assay, all stock solutions were made in D_2O except for **1b**. Stock solutions used in the assays were prepared as follows: a solution of **1b** (15 mM) was prepared by dissolving 10 mg of **1b** in 4 mL acetonitrile, a solution of sodium phosphate (500 mM) was prepared from 409 mg Na_2HPO_4 and 254 mg NaH_2PO_4 dissolved in 10 mL D_2O , a solution of desferal (10 mM) was prepared by dissolving 3 mg desferal in 455 μL D_2O , a solution of NADPH (30 mM) was prepared by dissolving 1 mg of NADPH sodium salt in 40 μL D_2O , the stock of cytochrome P450 reductase (120 U/mL) was prepared by dissolving 3 μL of a 260.4 U/mL stock solution of enzyme dissolved in 3.5 μL D_2O , and a solution of CD_3OD (15 M) was prepared from 610 μL CD_3OD in 390 μL D_2O . All stock solutions except cytochrome P450 reductase were degassed by three cycles of freeze-pump-thaw on a vacuum line. For preparation of the assays, the di-oxide **1b** (10 μL) was mixed with desferal (30 μL), sodium phosphate buffer (30 μL), NADPH (10 μL), and CD_3OD (10 μL of the 15 M CD_3OD stock in D_2O) and 209 μL of D_2O . Finally, the reactions were initiated by the addition of cytochrome P450 reductase stock solution (1 μL). The final volume of the assay mixture was 300 μL . These assays contained small amounts of residual exchangeable protium. The final mixtures contained approximately 99.5% D content in the water and, thus, small amounts ($\sim 0.5\%$) of CD_3OH will be present alongside much larger amounts of CD_3OD . Nonetheless, these traces of protium in the deuterium atom donor are not expected to represent a confounding factor in the interpretation isotope incorporation assays. Bond enthalpies significantly favor atom abstraction from the methyl group of methanol rather than the hydroxyl group (see Supporting Information for further discussion of this topic). Experimental evidence presented below confirmed that atom abstraction in this system occurs at the methyl group of methanol. Specifically, the formation of significant amounts of metabolites **8** clearly indicated that $\bullet\text{CD}_2\text{OH/D}$ and $\bullet\text{CH}_2\text{OH}$ were generated. In addition, assays in which additional steps were taken to remove the residual exchangeable protium sources gave identical results (Figure S8).

After 4 h incubation under argon at 25 °C, the proteins in the assay mixtures were removed by centrifugation through Amicon Microcon (YM3) filters. The filtrate was analyzed by Beckman Coulter HPLC employing a C18 reverse phase Betabasic column (5 μm particle

size, 150 Å pore size, 25 cm length, 4.6 mm i.d.) eluted with gradient starting from 5% B (0.1% trifluoacetic acid in acetonitrile) and 95% A (0.1% trifluoacetic acid in water) for 5 min followed by linear increase to 11% B in another 24 min, then the gradient was increased linearly to 80% of B within 6 min, and finally 80% of B was used to wash the column for 10 min. A flow rate of 1.0 mL/min was used and the products were monitored by their UV-absorbance at 240 nm. LC/ESI-MS experiments were carried out using an ion trap mass analyzer, on a LCQ FLEET instrument (Thermo Fisher Scientific). Positive ion electrospray was used as the means of ionization. The heated inlet capillary temperature was 375 °C and electrospray needle voltage was 5 kV. Nitrogen sheath gas was supplied at 45 psi and the LC/ESI-MS analysis was done in the positive ion mode. Relative collision energies of 35% were used when the ion trap mass spectrometry was operated in the MS/MS mode. Parent ions were selected manually (164, 165, 148, 149, 132, 133, 178, 180) and subsequent tandem mass spectrometry was performed automatically by XCalibur software (Thermo Fisher Scientific).

Results and Discussion

Bioreductively-Activated, Hypoxia-Selective DNA Strand Cleavage by **1b**

We synthesized **1b** by a literature route involving treatment of **1a** with *t*-butyl nitrite in DMF.^{3,44} We prepared the expected metabolite **3b** via the analogous reaction on **3a**.³⁸ In addition, we prepared a second expected^{15,16,23} metabolite **7** by treatment of **3b** with sodium dithionite in ethanol-water. We employed a plasmid-based assay to measure the ability of **1b** to cause bioreductively-activated DNA strand cleavage under hypoxic conditions. In this assay, oxidative DNA strand cleavage causes conversion of a supercoiled plasmid substrate (form I) to the open circular form II.⁴⁹⁻⁵² These two forms of plasmid DNA are then separated using agarose gel electrophoresis and visualized by staining with ethidium bromide.⁴⁹⁻⁵² This assay is especially useful for monitoring the direct DNA strand breaks generated by radical intermediates.^{53,54} Direct strand breaks induced by radicals typically arise via abstraction of hydrogen atoms from the 2-deoxyribose phosphate backbone of DNA.^{53,54} We used recombinant human NADPH:cytochrome P450 reductase to carry out one-electron reductive activation of **1b** because this or a related enzyme⁵⁵ is thought to be responsible for the intracellular activation of 1,2,4-benzotriazine 1,4-dioxides.^{43,56,57} For reactions carried out under hypoxic conditions, molecular oxygen was removed from stock solutions by freeze-pump-thaw degassing and the assay mixtures assembled and incubated in an inert atmosphere glove bag. Catalase, superoxide dismutase, and desferal were included as described previously^{21,32} to prevent potential background strand cleavage stemming from the conversion of adventitious molecular oxygen to reactive oxygen species.

We found that **1b** caused DNA strand cleavage when incubated with the plasmid substrate and the NADPH/NADPH:cytochrome P450 reductase enzyme system under hypoxic conditions (Figure 1). Across a range of concentrations (25-150 μM), the yields of DNA strand breaks generated by **1b** were comparable to those produced by **1a** and **1d**, two biologically-active compounds whose DNA-strand cleaving properties have been characterized previously (Figure 1).^{3,13,21,25,43} Control experiments showed that neither **1b** alone nor the NADPH/NADPH:cytochrome P450 reductase enzyme system (without **1b**)

caused significant amounts of DNA strand cleavage (Figure 1). Likewise, when **1b** was incubated with the enzyme alone (no NADPH), NADPH alone (no enzyme) or with the complete enzymatic reducing system under aerobic conditions no significant amounts DNA strand cleavage were observed (Figure S1). Further control experiments showed that compounds **3b** and **7**, two major metabolites generated in the hypoxic metabolism of **1b** (see below), did not cause DNA strand cleavage either alone or in the presence of the NADPH:cytochrome P450 reductase enzyme system under hypoxic conditions. We found that DNA strand cleavage by **1b** was substantially inhibited (60-90%) by the classical radical-scavenging agents⁵⁸ ethanol, methanol, *t*-butanol, DMSO, and mannitol (500 mM, Figure 2), analogous to the results observed previously for **1a** and **1d**. Of special importance to the studies described below, we found that methanol-*d*₄ (500 mM) efficiently quenched the DNA-cleaving intermediate generated upon enzymatic activation of **1b** (Figure S2). Overall, the reductively-activated, hypoxia-selective DNA-cleaving properties of **1b** closely resemble those of tirapazamine and other 1,2,4-benzotriazine 1,4-dioxides.^{13,21,25,43}

In Vitro Biochemical Metabolism of **1b**

In the case of other 1,2,4-benzotriazine 1,4-dioxides that have been characterized, DNA strand cleavage is accompanied by generation of the corresponding 1,2,4-benzotriazine 1-oxide **3** as the major metabolite (Scheme 1).^{15,23,25,27,28} Here, we used LC-MS/MS analysis to characterize the products generated by in vitro, cell-free, hypoxic metabolism of **1b** by NADPH:cytochrome P450 reductase in the presence of methanol as a hydrogen atom source. UV-vis detection of the resulting products (240 nm) revealed a mixture consisting of the starting material **1b** alongside several new metabolites (Figure 3). MS/MS analysis of the products, along with comparison to authentic synthetic standards, showed that the 1,4-dioxide **1b** eluted at 6.7 min, the expected mono-*N*-oxide **3b** eluted at 18.8 min and, the expected “no-oxide” metabolite **7** eluted at 17.7 min (Table 1). The minor metabolite eluting at 14.7 min was tentatively assigned the structure **8a** based upon its *m/z* of 178 in the LC-MS. Such a product could arise by a number of different mechanisms including addition of the methanol-derived radical, •CH₂OH, to **1b**, followed by either dehydration or loss of HO•.⁵⁹ An analogous mono-*N*-oxide product was previously observed to arise via the reaction of methyl radical with **1a**.⁵⁹

In Vitro Biochemical Metabolism of **1b** in Phosphate-Buffered D₂O-methanol-*d*₄

The results described above set the stage for isotopic labeling experiments designed to probe whether biochemical activation of **1b** generates an atom-abstracting drug radical intermediate such as **6**. As noted above, generation of an aryl radical such as **6** from **2b** in the presence of a deuterium atom donor will yield the corresponding deuterated drug metabolite **3c**,^{41,42} whereas release of hydroxyl radical from **2b** will generate the non-deuterated metabolite **3b**. It may be important to reiterate that the experiments described above demonstrated that methanol-*d*₄ efficiently quenches biochemically-activated DNA strand cleavage by **1b**, thus providing a clear indication that the DNA-cleaving intermediate generated following biochemical activation of **1b** does indeed react with methanol-*d*₄.

Thus, **1b** was incubated with the NADPH:cytochrome P450 reductase enzyme system under hypoxic conditions in phosphate-buffered D₂O containing methanol-*d*₄ (500 mM) and the

metabolites generated in this reaction were analyzed by LC-MS/MS. We observed that the spectrum of metabolites generated in the presence of phosphate-buffered D₂O/methanol-*d*₄ was identical to that observed in the H₂O/methanol experiment shown in Figure 3 (Figure S3). Importantly, LC-MS analysis revealed no significant deuterium incorporation into the major metabolite **3** (Figure 4). The relative abundances of ions in the isotope cluster for the [M+H]⁺ ion of **3** observed in these experiments matches that expected to arise from the natural abundances of ²H, and ¹³C in a molecule of this molecular formula. Similarly, the no-oxide metabolite showed no deuterium incorporation. Our LC-MS analysis revealed that the mass-to-charge ratio of the metabolite eluting at 14.7 min generated in the D₂O/methanol-*d*₄ experiment was two Daltons greater than the analogous product generated in the presence of non-deuterated methanol (Figure S4). This observation is consistent with the notion that the 14.7 min metabolite contains a CH₂OH or CD₂OH fragment derived from methanol or methanol-*d*₄ (the deuterium on the hydroxyl group of the CD₂OD fragment presumably was exchanged with protons from trifluoroacetic acid in the HPLC eluent during the LC-MS analysis). As noted above, **8a** and **8b** could reasonably arise via multiple reaction pathways; therefore, we cannot consider the formation of these products diagnostic for any particular mechanism.

Bioreductive Metabolism of the Deuterium-Containing Analog **1c**

Finally, we synthesized the deuterated analogue **1c** via treatment of **1a** with *t*-butyl nitrite in DMF-*d*₇.^{44,60} Availability of this labeled compound enabled us to undertake isotopetracking experiments complementary to the solvent-labeling experiments described above. Specifically, the dehydration mechanism proposed³⁸ to generate the radical **6** would result in *loss* of deuterium content during the conversion of **1c** to **3** when the reaction is carried out in the presence of protic solvents and hydrogen atom sources. In contrast, the hydroxyl radical mechanism will proceed with complete retention of label in the conversion of **1c** to **3**. LC-MS analysis of the mixture generated by NADPH:cytochrome P450 reductase-catalyzed metabolism of the deuterated analog **1c** revealed no significant loss of deuterium content in the enzymatic transformation of **1c** to the corresponding mono-*N*-oxide metabolite **3** (Figure S5). The observation that the deuterium content of the starting material **1c** was retained in **3** had the side benefit of demonstrating that a deuterium label does not “wash out” of the metabolite **3** under our reaction conditions. This serves as a control for the methanol-*d*₄ experiments described in the previous section, ruling out the possibility, albeit remote, that, in those experiments, deuterium was incorporated into the metabolite **3**, but subsequently was completely washed out prior to the mass spectrometric analysis.

Conclusions

The results presented here show that 1,2,4-benzotriazine 1,4-dioxide (**1b**) is able to carry out enzyme-activated, hypoxia-selective DNA strand cleavage analogous to the other benzotriazine di-*N*-oxides that have been characterized.^{21,25,43} Two complementary isotopic labeling experiments provided evidence *against* the generation of atom-abstracting drug radicals such as **6** following one-electron reductive activation of 1,2,4-benzotriazine 1,4-dioxide under hypoxic conditions. Accordingly, the data is consistent with a mechanism

involving release of the well-known DNA-damaging agent, hydroxyl radical from the reductively-activated drug intermediate **2b**.

It may be useful to consider how the results described here mesh with the earlier suggestion that a spin-trapped adducts of **2** and **6** were detected following microsomal reduction of **1b** in the presence of the nitron spin-trap PBN (*N*-tert-butylphenyl- α -nitron).³⁸ Importantly, recent computational analyses suggested that spin-trapping agents may not serve as “neutral observers” that report on the normal reactions of the bioreductively-activated radical intermediate **2**.²⁸ Rather, spin-trapping agents have the potential to react directly with **2**, in effect, short-circuiting its normal reactivity. Thus, various reactions of spin-trapping agents with **2b** – rather than with **6** – may yield the observed ESR spectra.^{28,37,38} It is difficult to rigorously define the structure of a spin-trapped radical using ESR and further work is required to determine the exact nature of the radicals captured by spin-trapping reagents during bio-reduction of **1b** and other analogs.

Overall, the results are consistent with the hypothesis that bioreductive activation of heterocyclic *N*-oxides under hypoxic conditions leads to the release of the highly cytotoxic reactive species, hydroxyl radical. This molecular mechanism may be relevant to the biological properties of many, structurally varied heterocyclic *N*-oxides under investigation as potential therapeutic agents for the treatment of cancer,^{7,61,62} tuberculosis,^{63,64} malaria,^{65,66} leishmaniasis,⁶⁶ Chagas disease,⁶⁷ and bacterial infections.⁶⁸

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This manuscript is dedicated to the memory of Victor Fung, Ph.D., a former Program Officer at NCI and former Scientific Review Officer of the Cancer Etiology study section of CSR, NIH, for his wisdom, compassion, integrity, his love of sciences and the arts, his incredible culinary skills, and above all, his contributions to the career development of so many investigators during his own distinguished career.

Funding: We thank the National Institutes of Health for partial support of this work (CA 100757).

References

1. Morgan G, Wardy R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. *Clin Oncol*. 2004; 16:549–560.
2. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. *Nat Rev Cancer*. 2011; 11:393–409. [PubMed: 21606941]
3. Kelson AB, McNamara JP, Pandey A, Ryan KJ, Dorie MJ, McAfee PA, Menke DR, Brown JM, Tracy M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. *Anti-Cancer Drug Design*. 1998; 13:575–592. [PubMed: 9755719]
4. Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA. Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine. *J Med Chem*. 2003; 46:169–182. [PubMed: 12502371]
5. Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, Denny WA. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. *J Med Chem*. 2008; 51:6853–6865. [PubMed: 18847185]

6. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. *J Med Chem.* 2007; 50:6392–6404. [PubMed: 18001018]
7. Xia Q, Zhang L, Zhang J, Sheng R, Yang B, He Q, Hu Y. Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine 1,4-dioxide derivatives. *Eur J Med Chem.* 2011; 46:919–926. [PubMed: 21281992]
8. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HDS, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. *Clin Cancer Res.* 2010; 16:4946–4957. [PubMed: 20732963]
9. Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW. 18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model. *J Nucl Med.* 2013; 54:1–8.
10. Priyadarsini KI, Tracy M, Wardman P. The one-electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine): A hypoxia-selective bioreductive drug. *Free Rad Res.* 1996; 25:393–399.
11. Lloyd RV, Duling DR, Rummyantseva GV, Mason RP, Bridson PK. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. *Mol Pharmacol.* 1991; 40:440–445. [PubMed: 1654517]
12. Wardman P, Priyadarsini KI, Dennis MF, Everett SA, Naylor MA, Patel KB, Stratford IJ, Stratford MRL, Tracy M. Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs. *Br J Cancer.* 1996; 74:S70–S74.
13. Laderoute KL, Wardman P, Rauth M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233). *Biochem Pharmacol.* 1988; 37:1487–1495. [PubMed: 3128984]
14. Silva JM, O'Brien PJ. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. *Br J Cancer.* 1993; 68:484–491. [PubMed: 8394729]
15. Laderoute K, Rauth AM. Identification of two major reduction products of the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide. *Biochem Pharmacol.* 1986; 35:3417–3420. [PubMed: 3768032]
16. Walton MI, Workman P. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075, SR 4233, NSC 130181) in mice. *J Pharmacol Exp Ther.* 1993; 265:938–947. [PubMed: 8496834]
17. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. *Int J Radiat Oncol Biol Phys.* 1986; 12:1239–1242. [PubMed: 3744945]
18. Zeman EM, Baker MA, Lemmon MJ, Pearson BA, Adams JA, Brown JM, Lee WW, Tracy M. Structure-activity relationships for benzotriazine di-N-oxides. *Int J Radiat Oncology Biol Phys.* 1989; 16:977–981.
19. Brown JM. SR4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. *Br J Cancer.* 1993; 67:1163–1170. [PubMed: 8512801]
20. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM. Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells. *Cancer Res.* 2008; 68:257–265. [PubMed: 18172318]
21. Daniels JS, Gates KS. DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (SR4233): Evidence for Involvement of Hydroxyl Radical. *J Am Chem Soc.* 1996; 118:3380–3385.
22. Kotandeniya D, Ganley B, Gates KS. Oxidative base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). *Bioorg Med Chem Lett.* 2002; 12:2325–2329. [PubMed: 12161126]

23. Fuchs T, Chowdhury G, Barnes CL, Gates KS. 3-Amino-1,2,4-benzotriazine 4-Oxide: Characterization of a New Metabolite Arising From Bioreductive Processing of the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine). *J Org Chem.* 2001; 66:107–114. [PubMed: 11429885]
24. Birincioglu M, Jaruga P, Chowdhury G, Rodriguez H, Dizdaroglu M, Gates KS. DNA Base Damage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine). *J Am Chem Soc.* 2003; 125:11607–11615. [PubMed: 13129365]
25. Junnotula V, Sarkar U, Sinha S, Gates KS. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxides: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide. *J Am Chem Soc.* 2009; 131:1015–1024. [PubMed: 19117394]
26. Chowdhury G, Junnotula V, Daniels JS, Greenberg MM, Gates KS. DNA strand damage analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O₂. *J Am Chem Soc.* 2007; 129:12870–12877. [PubMed: 17900117]
27. Yin J, Glaser R, Gates KS. On the Reaction Mechanism of Tirapazamine Reduction Chemistry: Unimolecular N-OH Homolysis, Stepwise Dehydration, or Triazene Ring-Opening. *Chem Res Toxicol.* 2012; 25:634–645. [PubMed: 22390168]
28. Yin J, Glaser R, Gates KS. Electron and Spin-Density Analysis of Tirapazamine Reduction Chemistry. *Chem Res Toxicol.* 2012; 25:620–633. [PubMed: 22390194]
29. Daniels JS, Gates KS, Tronche C, Greenberg MM. Direct evidence for bimodal DNA damage induced by tirapazamine. *Chem Res Toxicol.* 1998; 11:1254–1257. [PubMed: 9815184]
30. Ganley B, Chowdhury G, Bhansali J, Daniels JS, Gates KS. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide. *Bioorg Med Chem.* 2001; 9:2395–2401. [PubMed: 11553481]
31. Junnotula V, Rajapakse A, Abrillaga L, Lopez de Cerain A, Solano B, Villar R, Monge A, Gates KS. DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide. *Bioorg Med Chem.* 2010; 18:3125–3132. [PubMed: 20371184]
32. Chowdhury G, Kotandeniya D, Barnes CL, Gates KS. Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. *Chem Res Toxicol.* 2004; 17:1399–1405. [PubMed: 15540937]
33. Fuchs T, Gates KS, Hwang JT, Greenberg MM. Photosensitization of Guanine-Specific DNA Damage by a Cyano-Substituted Quinoxaline Di-N-Oxide. *Chem Res Toxicol.* 1999; 12:1190–1194. [PubMed: 10604868]
34. Priyadarsini KI, Dennis MF, Naylor MA, Stratford MRL, Wardman P. Free radical intermediates in the reduction of quinoxaline N-oxide antitumor drugs: redox and prototropic reactions. *J Am Chem Soc.* 1996; 118:5648–5654.
35. Chowdhury G, Sarkar U, Pullen S, Wilson WR, Rajapakse A, Fuchs-Knotts T, Gates KS. DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions. *Chem Res Toxicol.* 2012; 25:197–206. [PubMed: 22084973]
36. Shinde SS, Anderson RF, Hay MP, Gamage SA, Denny WA. Oxidation of 2-Deoxyribose by Benzotriazinyl Radicals of Antitumor 3-Amino-1,2,4-benzotriazine 1,4-Dioxides. *J Am Chem Soc.* 2004; 126:7865–7874. [PubMed: 15212534]
37. Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF. Spin trapping of radicals other than the hydroxyl radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. *J Am Chem Soc.* 2009; 131:14220–14221. [PubMed: 19772319]
38. Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF. Characterization of Radicals Formed Following Enzymatic Reduction of 3-Substituted Analogues of the Hypoxia-Selective Cytotoxin 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (Tirapazamine). *J Am Chem Soc.* 2010; 132:2591–2599. [PubMed: 20141134]
39. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Activation of 3-Amino-1,2,4-benzotriazine 1,4-Dioxide Antitumor Agents to Oxidizing Species Following Their One-Electron Reduction. *J Am Chem Soc.* 2003; 125:748–756. [PubMed: 12526674]

40. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. *Org Biomol Chem*. 2005; 3:2167–2174. [PubMed: 15917906]
41. Chin DH, Goldberg IH. Sources of hydrogen abstraction by activated neocarzinostatin chromophore. *Biochemistry*. 1993; 32:3611–3616. [PubMed: 8466903]
42. Štefane B, Polanc S. CAN-Mediated Oxidation of Electron-Deficient Aryl and Heteroaryl Hydrazines and Hydrazides. *SYNLETT*. 2008:1279–1282.
43. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. *Carcinogenesis*. 1994; 15:1503–1510. [PubMed: 8055626]
44. Doyle MP, Dellaria JFJ, Siegfried B, Bishop WW. Reductive amination of arylamine by alkyl nitrites in N,N-dimethylformamide. A direct conversion of arylamines to aromatic hydrocarbons. *J Org Chem*. 1977; 42:4394–4398.
45. Bender ML, Clement GE, Kézdy FJ, Heck HDA. The Correlation of the pH (pD) Dependence and the Stepwise Mechanism of α - Chymotrypsin-Catalyzed Reactions. *J Am Chem Soc*. 1964; 86:3680–3690.
46. Walde P, Peng Q, F NW, Battistel E, Luisi PL. Structure and activity of trypsin in reverse micelles. *Eur J Biochem*. 1988; 173:401–409. [PubMed: 3360018]
47. Mason JC, Tennant G. Heterocyclic N-oxides. Part VI. Synthesis and Nuclear Magnetic Resonance Spectra of 3-Aminobenzo-1,2,4-triazines and their mono and di-N-oxides. *J Chem Soc B*. 1970:911–916.
48. Boyd M, Hay MP, Boyd PDW. Complete ¹H, ¹³C, and ¹⁵N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides. *Mag Res Chem*. 2006; 44:948–954.
49. Jonson PH, Grossman LI. Electrophoresis of DNA in agarose gels. Optimizing separations of conformational isomers of double and single-stranded DNAs. *Biochemistry*. 1977; 16:4217–4224. [PubMed: 332225]
50. Mirabelli CK, Huang CH, Fenwick RG, Crooke ST. Quantitative measurement of single- and double-strand breakage of DNA in Escherichia coli by the antitumor antibiotics bleomycin and talisomycin. *Antimicrobial Agents Chemother*. 1985; 27:460–467.
51. Oppenheim A. Separation of closed circular DNA from linear DNA by electrophoresis in two dimensions in agarose gels. *Nucleic Acids Res*. 1981; 9:6805–6812. [PubMed: 6278448]
52. Hintermann G, Fischer HM, Crameri R, Hutter R. Simple procedure for distinguishing CCC, OC, and L forms of plasmid DNA by agarose gel electrophoresis. *Plasmid*. 1981; 5:371–373. [PubMed: 7267812]
53. Greenberg MM. Elucidating DNA damage and repair processes by independently generating reactive and metastable intermediates. *Org Biomol Chem*. 2007; 5:18–30. [PubMed: 17164902]
54. Gates KS. An overview of chemical processes that damage cellular DNA: spontaneous hydrolysis, alkylation, and reactions with radicals. *Chem Res Toxicol*. 2009; 22:1747–1760. [PubMed: 19757819]
55. Delahoussaye YM, Evans JM, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. *Biochem Pharmacol*. 2001; 62:1201–1209. [PubMed: 11705453]
56. Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Enzymology of tirapazamine metabolism: a review. *Anti-Cancer Drug Des*. 1998; 13:541–573.
57. Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive activation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233, WIN 59075) by mouse liver. *Biochem Pharmacol*. 1992; 44:251–259. [PubMed: 1642640]
58. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. *Methods Enzymol*. 1990; 186:1–85. [PubMed: 2172697]
59. Fuchs T, Barnes CL, Gates KS. Crystal Structure of 3-Amino-5-methyl-1,2,4-benzotriazine 1-Oxide: Evidence for Formation of a Covalent Attachment Between a Carbon-Centered Radical and the Antitumor Agent Tirapazamine. *J Chem Crystallog*. 2001; 31:387–391.

60. Markgraf JH, Chang R, Cort JR, Durant LJ, Finkelstein M, Gross AW, Lavyne MH, Peterson RC, Ross SD. Protodediazoniation of aryldiazonium fluoroborates by dimethylformamide. *Tetrahedron*. 1997; 53:10009–10018.
61. Solano B, Junnotula V, Marin A, Villar R, Burguete A, Vicente E, Perez-Silanes S, Monge A, Dutta S, Sarkar U, Gates KS. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide derivatives and their reduced analogues. *J Med Chem*. 2007; 50:5485–5492. [PubMed: 17910426]
62. Monge A, Martinez-Crespo FJ, Lopez de Cerain A, Palop JA, Narro S, Senador V, Marin A, Sainz Y, Gonzalez M, Hamilton E, Barker AJ, Clarke ED, Greenhow DT. Hypoxia-Selective Agents Derived from 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides. 2. *J Med Chem*. 1995; 38:4488–4494. [PubMed: 7473576]
63. Chopra S, Koolpe GA, Tambo-ong AA, Matsuyama KN, Ryan KJ, Tran TB, Doppalapudi RS, Riccio ES, Iyer LV, Green CE, Wan B, Franzblau SG, Madrid PB. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating *Mycobacterium tuberculosis*. *J Med Chem*. 2012; 55:6047–6060. [PubMed: 22691154]
64. Vicente E, Perez-Silanes S, Lima LM, Ancizu S, Burguete A, Solano B, Villar R, Aldana I, Monge A. Selective activity against *Mycobacterium tuberculosis* of new quinoxaline 1,4-di-N-oxides. *Bioorg Med Chem*. 2009; 17:385–389. [PubMed: 19058970]
65. Barea C, Pabón A, Castillo D, Zimic M, Quillano M, Galiano S, Pérez-Silanes S, Monge A, Deharo E, Aldana I. New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities. *Bioorg Med Chem Lett*. 2011; 21:4498–4502. [PubMed: 21724395]
66. Barea C, Pabón A, Pérez-Silanes S, Galiano S, Gonzalez G, Monge A, Deharo E, Aldana I. New amide derivatives of quinoxaline 1,4-di-N-oxide with leishmanicidal and antiplasmodial activities. *Molecules*. 2013; 18:4718–4727. [PubMed: 23609622]
67. Vicente E, Cuchowicz PR, Benítez D, Castro EA, Cerecetto H, González M, Monge A. Anti-*T. cruzi* activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. *Bioorg Med Chem Lett*. 2010; 20:4831–4835. [PubMed: 20634064]
68. Gund PH, Berkelhammer G. New antibacterial quinoxaline N,N-dioxide derivatives. *J Med Chem*. 1971; 14:992. [PubMed: 4940180]

Figure 1.

Bioelectrochemically-activated DNA strand cleavage by **1b** under hypoxic conditions. Panel A. Concentration-dependent DNA strand cleavage by **1b**. Supercoiled plasmid DNA (pGL2-basic, 33 $\mu\text{g/mL}$) was incubated with **1b** (25-150 μM), NADPH:cytochrome P450 reductase (33 mU/mL), NADPH (500 μM), catalase (100 $\mu\text{g/mL}$), superoxide dismutase (10 $\mu\text{g/mL}$), sodium phosphate buffer (50 mM, pH 7.0) and desferal (1 mM) under anaerobic conditions at room temperature for 4 h, followed by agarose gel electrophoretic analysis. Strand breaks per plasmid DNA molecule (S) were calculated using the equation $S = -\ln f_I$ where f_I is the fraction of plasmid present as form I. Lane 1, DNA alone ($S = 0.35 \pm 0.14$); lane 2, enzyme system alone ($S = 0.32 \pm 0.11$); lane 3, **1b** alone (150 μM , $S = 0.38 \pm 0.17$); Lanes 4-9, enzyme system + **1b** at 25 μM ($S = 0.49 \pm 0.13$), 50 μM ($S = 0.76 \pm 0.05$), 75 μM ($S = 1.07 \pm 0.08$), 100 μM ($S = 1.30 \pm 0.09$), 125 μM ($S = 1.42 \pm 0.07$), 150 μM ($S = 1.62 \pm 0.14$). Panel B. Comparison of concentration-dependent DNA strand breakage by **1a**, **1b**, and **1d** under hypoxic conditions. Strand cleavage by various concentrations (25-150 μM) of the three different compounds was carried out as described above. Background cleavage present in the untreated plasmid was subtracted to allow direct comparison of DNA cleavage yields between different experiments.

Figure 2.

Radical-scavenging agents inhibit bioreductively-activated DNA strand cleavage by **1b**. Column 1 shows the strand cleavage yield generated by **1b** (50 μ M) under the standard hypoxic reaction conditions described in the Experimental Section and the Legend of Figure 1. Columns 2-6 illustrate the cleavage yields under those same standard conditions except in the presence of the indicated radical scavenging agent (500 mM). Background cleavage present in the untreated plasmid was subtracted to allow direct comparison of DNA cleavage yields between different experiments. The number of strand breaks per plasmid DNA molecule (S) was calculated using the equation $S = -\ln f_1$ where f_1 is the fraction of plasmid present as form I.

Figure 3.

Reverse-phase HPLC chromatogram (UV 254 nm) of the products generated by in vitro hypoxic metabolism of **1b** in the presence of methanol.

Figure 4.

Hypoxic metabolism of **1b** in phosphate-buffered D₂O/CD₃OD does not lead to incorporation of deuterium into the metabolite **3**. LC-MS of the mono-*N*-oxide metabolite **3** generated by hypoxic metabolism of **1b**. Panel A, isotope cluster for the [M+H]⁺ ion of **3** generated in phosphate-buffered H₂O/CH₃OH (relative peak intensities for *m/z* 148:149:150 = 100:7.9:0.5). Panel B, isotope cluster for the [M+H]⁺ ion of **3** generated in phosphate-buffered D₂O/CD₃OD (relative peak intensities for *m/z* 148:149:150 = 100:8.2:0.6).

Scheme 1.

Structures.

Table 1

LC-MS/MS properties of the mixture generated by in vitro metabolism of **1b** under hypoxic conditions in the presence of CH₃OH.

Metabolites	Retention time	[M+H] ⁺	MS/MS fragments
1b	6.5	164	147, 137, 119, 93, 92, 65
7	17.7	132	105, 77
3b	18.8	148	120, 93, 92, 65
8a	14.6	178	160, 132, 120, 104, 93, 92, 77, 65